The tuberculosis vaccine Bacillus Calmette-Guérin (BCG) may reshape the brain’s immune environment, potentially offering a new pathway to manage Alzheimer’s disease. According to a study published in Communications Medicine, the vaccine triggers “trained immunity,” a process where innate immune cells undergo functional reprogramming that can influence brain health and Alzheimer’s-related biomarkers in healthy older adults.
BCG Vaccine and the Concept of Trained Immunity
Researchers are exploring whether the BCG vaccine—traditionally used to protect infants against tuberculosis—can provide cognitive benefits later in life. Mahesh Chandra Kodali, a co-first author and senior research fellow at Harvard Medical School and Massachusetts General Hospital, describes BCG as a prime example of “trained immunity.”
In this process, microbial stimuli cause long-lasting functional changes in innate immune cells. These changes persist for months or even years, extending the vaccine’s protective influence beyond its primary target of tuberculosis. According to the study, this reprogramming can modulate neuroinflammation and reduce amyloid pathology, which is the clumping of proteins in the brain often associated with Alzheimer’s disease.
Did you know?
The BCG vaccine is delivered through the skin and is one of the most widely studied vaccines in the world. Its potential for “reprogramming” the immune system has sparked interest in its off-label applications for neurodegenerative conditions.
Impact on Alzheimer’s Biomarkers in Older Adults
To determine if BCG influences biological processes relevant to Alzheimer’s, researchers recruited 23 adults aged 55 and older. The cohort was split between 11 participants already showing physical signs of Alzheimer’s pathology and 12 healthy participants without such signs. Over a 12-month period, the team collected cerebrospinal fluid and peripheral blood samples.
The results showed distinct shifts in amyloid-beta levels among healthy participants. In those without pre-existing pathology, amyloid levels in the brain and spinal fluid declined, while levels in the blood increased. The authors noted that this shift in balance was not observed in the participants who already had Alzheimer’s pathology, suggesting the timing of the vaccination is critical. The findings imply that early intervention may be necessary to affect protein clearance from the central nervous system.
Future Directions for Clinical Research
While the study provides a biological explanation for links between BCG and lower Alzheimer’s risk, the authors emphasize that larger, randomized clinical trials are required. Future research must distinguish between the effects of prior BCG vaccination, potential latent tuberculosis infections, and the natural progression of Alzheimer’s disease.
According to Kodali, the study confirms that controlled mycobacterial immune stimulation can influence biological pathways related to Alzheimer’s. However, the medical community currently lacks definitive evidence to confirm whether this approach can effectively prevent or treat the disease in a clinical setting.
Pro Tips for Understanding Immune Modulation
- Focus on Biomarkers: Scientific studies often use fluid samples to track “biomarkers,” which act as biological indicators of disease progression.
- Context Matters: “Trained immunity” is a specific physiological response; it is distinct from the adaptive immunity typically associated with standard vaccine responses.
Frequently Asked Questions
Can the BCG vaccine treat Alzheimer’s disease?
Not currently. While the study found that BCG influenced Alzheimer’s-related biomarkers in healthy older adults, the authors state that larger studies are needed to determine if it can prevent or treat the disease.
What is “trained immunity”?
Trained immunity is a process where innate immune cells undergo long-lasting functional reprogramming after exposure to specific microbial stimuli, allowing them to respond differently to future triggers.
Why was the timing of the vaccine important in the study?
The study observed amyloid-beta shifts in healthy participants but not in those who already had Alzheimer’s pathology, suggesting the vaccine may be more effective when administered before the disease has progressed.
Worth a look
